Hangzhou pilotnew new policy on biomaterial quarantine reform to help the innovation and development of biopharmaceutical industry

[
pharmacy network policies and regulations] Following Beijing, Tianjin and Shanghai, Hangzhou, biological material will be piloted entry quarantine reform of the New DealRecently, the General Administration of Customs formally approved the entry of new initiatives quarantine Hangzhou pilot reform of biological material, it is expected to benefit more than 1,000 scientific research institutions, university institutions, import and export enterprise and pharmaceutical R & D companiesNew Deal reforms will continue to release energy, bio-pharmaceutical industry to promote innovation and development in HangzhouIn recent years, the rapid development of bio-pharmaceutical industry in Hangzhou, more vigorous biological experiments for high-end imported material needs, the type of biological material imported more numerousImport facilitation of biological material, a key link in Hangzhou biomedical technology to enhance the level of research and development, innovation and boost bio-pharmaceutical industry development in Hangzhou, to promote the industry supply-side structural reforms organismsThethe quarantine launched the New Deal reforms of biological material for three good convenience biological imported materialsFirst, shorten the entry specific-pathogen-free (SPF for short) mice isolation period, to meet the entry SPF mice or rats entry quarantine certain conditions will be 30 days to adjust to 14 days; the second is to improve the regulatory measures, import gene animals and plants and their associated microorganisms detected by DNA / RNA, from official quarantine exporting country / region certificates, accompanying foreign ingredients that provide instructions and safety notices were issued by the time of entry, can be directly released after the port inspection qualified; Third, simplifying entry approving experimental animal quarantine field, specify the entry SPF rat isolated field use permit by the handle Pipi adjusted to handle a multiple use within 6 monthsIt is reported that, in addition to the dividend policy reform, customs are also fully support the Hangzhou Qiantang New build biomedical industry import animal experiment platform, the introduction of the world's leading supplier of model mice Jackson Laboratory in the United States, will Hang the establishment of China's SPF Laboratory animal production CenterHangzhou, the bio-pharmaceutical industry as an important part of industrial clusters "1 + 6", increasing industrial layout, and actively cultivate one hundred billion biomedical industry cluster, to create biomedical innovation have global influence cityIn recent years, Hangzhou scale bio-pharmaceutical industry to maintain rapid growth, in 2017 the regulations pharmaceutical industrial output value exceeded 50 billion yuan in Hangzhou, from January to October 2018, the new bio-pharmaceutical enterprises 3870, an increase of 26%, the new registered capital of 30.2 billion yuan, an increase of 39%present, Hangzhou has formed a new chemical drugs, modern medicine, biotechnology, pharmaceuticals, and other segments of enterprise clusters, gathering Beta Pharma, Huadong Medicine, Tiger pharmaceuticals, diagnostic Dean , Nuobei Kang and other leading domestic core business, build a biomedical innovation chain integration of the whole eco-system integrationAccording to "the opinions innovation and development of bio-pharmaceutical industry in Hangzhou", plans to 2022, will initially be built in Hangzhou domestic leader in biomedical research and development and industrialization of high ground, the main business revenue reached 100 billion yuan above, the city has become the biomedical innovation global influencethe release of new entry inspection and quarantine measures biomaterials reform, will be able to better meet the Hangzhou area biomedical companies and research institutions required to supply biological materials, benefiting more than 1,000 scientific research institutions, university institutions, import and export enterprise and pharmaceutical R & D enterprise, help innovation platform, industry leading talent to accelerate the gathering, help Hangzhou biomedical industry bigger and stronger, so that the rapid development of bio-pharmaceutical industry, to better seize new development opportunities .